Methods Thirty-five aGCTs were subjected to massively parallel sequencing targeting 468 cancer-related genes (7 primary aGCTs that did not recur >4 years, 9 primary and matched recurrent aGCTs, 10 recurrent aGCTs). These cases and additional 12 aGCTs (n=3, primary aGCTs that did not recur; n=9, recurrent aGCTs) were subjected to Sanger sequencing analysis of the TERT promoter.

Results All aGCTs included harbored the FOXL2 p.C134W hotspot mutation. A significantly higher frequency of TERT promoter mutations was found in recurrent (64%) than in primary aGCTs (26%; p=0.017). Moreover, aGCT recurrences harbored a higher frequency of somatic KMT2D and TP53 mutations (16%, each) than primary aGCTs with subsequent recurrences (11% and 0%) and primary aGCTs without subsequent recurrences (14% and 0%). We identified a higher frequency of CDKN2A/B homozygous deletions in recurrent (16%) than in primary aGCTs (6%), and other gene alterations restricted to recurrent aGCTs. Pathway analysis revealed that aGCTs are underpinned by genetic alterations affecting the cell cycle pathway. Clonal decomposition of matched primary and recurrent aGCTs showed that aGCTs display multiple clones at diagnosis and relapse.

Conclusions Our findings suggest that although FOXL2 plays a crucial role in the tumorigenesis of aGCTs, recurrences might be associated with genetic alterations affecting TERT, cell cycle-related genes such as TP53 and CDKN2A/B, and other cancer-related genes, including KMT2D, TET2 and EPHAS.

IGCS19-0511

MUCINOUS OVARIAN CARCINOMA: THERAPEUTIC OPTIONS OLD AND NEW

Objective Mucinous ovarian carcinoma (MOC) is a rare ovarian cancer subtype that responds poorly to conventional chemotherapy. Recurrent and advanced disease have poor survival and there are no specific guidelines for their treatment. We used a large cohort of genomic and immunohistochemical data to evaluate the likelihood of success of possible therapeutic interventions.

Methods We used DNA sequencing data (n=185) and immunohistochemistry data was obtained for CK7, CK20, PAX8, p16, CDX2, HER2 and ER (n=256) and tumour infiltrating lymphocytes were counted on H&E stained slides (n=40).

Results Therapies exploiting homologous recombination deficiency are unlikely to be effective in MOC, as only 1.5% had a homologous recombination deficiency score of more than 50. Mismatch repair deficiency was very rare (<1%). Most cases had low lymphocyte counts, corresponding to a moderate mutation load. Events that suggest an existing targeted therapy include: ERBB2 amplification (26%), ERBB3 mutation (4%) and BRAF mutation (9%). Novel agents currently in clinical trials targeting genetic events such as TP53 missense mutation (46%), RNF43 mutation (11%), PIK3CA mutation (8%) and KRAS/ NRAS mutations (66%).

Conclusions MOC is genetically diverse but with a number of potential targets. Importantly, the clinically observed lack of response to cisplatin is supported by a corresponding lack of a genomic signature, and MOC are unlikely to respond to PARP inhibitors. The role of immunotherapy is unclear. Testing novel therapeutic options in appropriate patient-derived models will be crucial and we are currently developing organoid cultures from this disease.

Plenary 3

IGCS19-0583


Objective To compare the long-term oncologic outcomes after minimally invasive surgery (robot assisted/laparoscopic radical hysterectomy) (MIS) versus abdominal radical hysterectomy (ARH) for early-stage cervical cancer (CC).

Methods This is a large single center retrospective study. From our institution’s patient registry, we identified a total of 587 early-stage cervical cancer patients who underwent either MIS or ARH between 2000 and 2017. We excluded the following patients from the final analysis: (1) received neo-adjuvant treatment prior to surgery; (2) had histologic types other than squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma; (3) were double primary cancer cases; (4) had stages higher than stageIB1 (FIGO 2009). We included only patients who underwent radical hysterectomy for early-stage cervical cancer and radical parametrectomy for stumpm carcinoma patients in our study population.

Results In total, 230 and 357 patients were assigned to the MIS and ARH groups, retrospectively. There were no significant differences for any demographics including age, stage, histology. Five-year recurrence free survival was 88.6% (95% CI, 83.4%- 92.3%) and 93.5% (95% CI, 90,4%- 95.7%), (p=0.04) respectively in the MIS and ARH group, and the five-year cancer specific survival was 95.4% (95% CI, 90.9%- 97.7%) and 97.4% (95% CI, 95.1%- 98.7%), (p=0.12) in the MIS and ARH group, respectively. MIS group have more peritoneal combined relapses comparing ARH (p=0.02). The relapse rate tended to be highest for squamous cell carcinoma in MIS group (p=0.09). Disease free survival and cancer specific survival were worse in the MIS group p- value= 0.04 and 0.12 respectively.
Conclusions
MIS was associated with a higher recurrence rate and mostly of peritoneal-combined type than ARH. MIS tended to have a higher mortality rate than ARH although not statistically significant in patients with early-stage cervical cancer cases.

IGCS19-0577

ORAL APIXABAN COMPARED TO SUBCUTANEOUS ENOXAPARIN FOR THROMBOPROPHYLAXIS IN WOMEN UNDERGOING SURGERY FOR SUSPECTED GYNECOLOGIC CANCER: FINAL RESULTS OF A MULTI-INSTITUTIONAL RANDOMIZED, CONTROLLED TRIAL


University of Colorado, Gynecologic Oncology, Denver, USA; University of Colorado School of Medicine, Gynecologic Oncology, Aurora, USA; University of Southern California, Gynecologic Oncology, Los Angeles, USA

Objectives
Venous thromboembolism (VTE) is a serious complication following gynecologic oncology surgery with 26% DVT and 9% pulmonary embolism rates. Current guidelines recommend subcutaneous enoxaparin for thromboprophylaxis.

We evaluated safety of apixaban (oral factor Xa inhibitor) versus enoxaparin for post-operative thromboprophylaxis in women with suspected gynecologic cancer.

Methods
A randomized study determined safety (major bleeding) of apixaban versus enoxaparin. Secondary outcomes included VTE, adverse events (AE), satisfaction. Women (18–89) were randomized to 28-days of 2.5mg apixaban BID or 40mg enoxaparin QD and followed for 90-days. Chi square and Fisher’s exact statistics were used; P<0.05 determined significance.

Results
Four hundred women completed therapy (mean age 56.6 years; mean BMI 28.5). Groups were similar for race, cancer diagnosis/ stage, and surgery. Seventy-eight percent of surgeries were open laparotomies; 70% involved hysterectomy. Two major bleeding events occurred on treatment: 1/205 in apixaban arm vs. 1/195 in enoxaparin arm (OR=0.95; 95%CI: 0.06–15.1; P=0.972). Five VTE events occurred: 2/205 vs. 3/195 respectively (OR=0.63; 95%CI: 0.12–3.75; P=0.616). Women receiving apixaban were 98% less likely to report pain (OR= 0.02, 95% CI 0.01–0.05, P<0.001) and 99% less likely to report difficulty administering treatment (OR= 0.01, 95% CI 0.001–0.13, P<0.001) compared to enoxaparin. There were 97 related AEs; AEs were rare (2%) and similar: wound infection (P=0.745), wound dehiscence (P=0.100), arthralgia (P=0.321), dizziness (P=0.078), vaginal bleeding (P=0.410), and headache (P=0.875).

Conclusions
Apixaban is a safe alternative to enoxaparin for thromboprophylaxis following gynecologic oncology surgery. Women taking apixaban had less pain and difficulty administering treatment. Efficacy of apixaban to prevent VTE is hypothesized as equivalent to enoxaparin.

IGCS19-0693

ROBOTIC-ASSISTED RADICAL HYSTERECTOMY (RRH) FOR EARLY STAGE CERVICAL CANCER (CC): PATTERNS OF RECURRENCE, SURVIVAL, AND THE SURGEON EXPERIENCE FACTOR


AdvenHealth Cancer Institute, Gynecologic Oncology, Orlando- FL 32804, USA

Objectives
To evaluate factors associated with recurrence and survival after RRH for CC.

Methods
Pts with early stage CC who underwent RRH(4/2007–12/2017) were evaluated. Inclusion criteria: >one year follow up, adenocarcinoma or squamous carcinoma, stage IA2 or IB1(FIGO 2014 guidelines), and pathologic tumor size(TS) of ≤4 cm. The first 10 learning curve cases per surgeon (A) were compared to all subsequent cases (B).

Results
144 RRH pts were identified and 90 met inclusion criteria. There were 40 A and 50 B patients. Median follow up was 61±34.3 months (A=71.5, B=52.5). There were 7 (7.8%) recurrences with median DFS of 12±8.3 months. Recurrence in A(n=6, 15%) exceeded B(n=1, 2%) (p=0.025). DSDR was 10% A v 2% B (p=0.184). The 4.5 yr DFS was 84.8%(95 CI ±7%) in A v 98%(95 CI ±3%) in B. Positive vaginal margin status(A=10% v B=0%, p=0.034) was the only difference. All recurrences had TS £21 cm. Of the 42 TS £2 cm, 5/14(36%) adenocarcinoma recurred compared to 2/28